Pramod Khedekar

Pramod Khedekar

Auto-generated profile, based on publicly available information

Pramod Khedekar

Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, Maharashtra, 440033, India

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2026 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
DWDeepali Wanode
Deepali Wanode
DNDeweshri Nandurkar
Deweshri Nandurkar
MAMegha Ambatkar
Megha Ambatkar
NRNilesh Ramesh Rarokar
Nilesh Ramesh Rarokar
PKPramod Khedekar
Pramod Khedekar
The field of cancer research has witnessed a surge in the exploration of novel therapeutic agents, with pyrazole derivatives emerging as promising candidates in the quest for effective anticancer treatments. This comprehensive review provides an in-depth analysis of the research landscape surrounding pyrazole derivatives as potential anticancer agents over the period from 2012 to 2024. Many synthetic pyrazole derivatives have been approved by the FDA and used as chemotherapeutic medicines, and some are under clinical trials, also reported in this article. The review aims to serve as a valuable resource for researchers, guiding future investigations and fostering the development of innovative pyrazole-based anticancer therapeutics.

24 March 2026 in Discover Chemistry
Verified
Journal Article
Open access
SWSuchita Waghmare
Suchita Waghmare
UHUjban Hussain
Ujban Hussain
RPRohini Palekar
Rohini Palekar
PBPratiksha Bramhe
Pratiksha Bramhe
NRNilesh Ramesh Rarokar
Nilesh Ramesh Rarokar
PKPramod Khedekar
Pramod Khedekar

6 March 2026 in RSC Pharmaceutics
Verified
Journal Article
Open access
PDF file
SWSuchita Waghmare
Suchita Waghmare
RPRohini Palekar
Rohini Palekar
PBPratiksha Bramhe
Pratiksha Bramhe
NRNilesh Ramesh Rarokar
Nilesh Ramesh Rarokar
PKPramod Khedekar
Pramod Khedekar
Tofacitinib, a Janus kinase (JAK) inhibitor clinically approved for rheumatoid arthritis, holds significant potential for repurposing in breast cancer therapy due to its ability to suppress the oncogenic STAT3 signaling pathway; however, its therapeutic application is hindered by poor aqueous solubility, rapid systemic clearance, and non-specific distribution. To address these limitations, this study aimed to develop hyaluronic acid (HA)-decorated Pluronic F127 (PF127) micelles to enhance the solubility, bioavailability, and targeted delivery of Tofacitinib to CD44-overexpressing breast cancer cells. A Quality by Design (QbD) approach utilizing a Box–Behnken design (BBD) was employed to systematically optimize critical process parameters—drug-to-polymer ratio, polymer concentration, and stirring temperature—to minimize particle size and polydispersity index (PDI) while maximizing entrapment efficiency. The optimized micelles exhibited a uniform particle size of 159.2 ± 3.8 nm, a narrow PDI of 0.221, a high entrapment efficiency of 91.14%, and a negative zeta potential of −24.6 mV, ensuring colloidal stability. In vitro evaluation demonstrated a sustained, diffusion-controlled drug release profile and significantly enhanced cytotoxicity against MCF-7 breast cancer cells (IC50 14.2 µg mL−1) compared to the free drug (IC50 46.8 µg mL−1), attributed to CD44-mediated cellular uptake. Furthermore, in vivo pharmacokinetic analysis in Wistar rats revealed a 4.3-fold increase in oral bioavailability and a prolonged elimination half-life compared to free Tofacitinib, while histopathological studies confirmed the formulation's biocompatibility and safety in major organs. These findings collectively support the viability of the QbD-optimized HA–PF127 micellar system as a promising nanocarrier platform for the effective oral repurposing of Tofacitinib in breast cancer treatment.

1 August 2025 in Russian Journal of General Chemistry
Verified
Journal Article
Closed access
PDF file
DWD. Wanode
D. Wanode
DND. Nandurkar
D. Nandurkar
PKP. Khedekar
P. Khedekar
In this study, we present comprehensive work on synthesis, and anticancer evaluation of a new series of benzothiazole-pyrazole hybrids. The structures of the synthesized compounds were confirmed using a comprehensive suite of analytical techniques, including 1H, 13C NMR, FT-IR, and HRMS. Among the series, the hybrid compound featuring a para-fluorophenyl substituent on the pyrazole ring exhibited notable in vitro anticancer activity compared to standard 5-fluorouracil against the MCF-7 cell line. To support the experimental findings, in silico studies were performed using physics-based approaches such as AutoDock Vina, molecular dynamics (MD) simulations, and MM-GBSA calculations. These studies revealed strong binding affinity of the compound toward the target protein (PDB ID: 4AGC), with key interactions involving amino acid residues ALA113A, ILE120A, LEU121A, ILE124A, LEU201A, and ILE226A. Overall, this compound emerges as a promising lead candidate for further development in anticancer drug discovery.

8 April 2026 in Asian Journal of Chemistry
Verified
Journal Article
Open access
KBKumud P. Bhendarkar
Kumud P. Bhendarkar
DWDeepali M. Wanode
Deepali M. Wanode
PKPramod B. Khedekar
Pramod B. Khedekar
In this work, few new pyrazoline derivatives Py1-Py5 were synthesised, characterised and their potential as EGFR kinase inhibitors was assessed. The target compounds were synthesized via Claisen-Schmidt condensation, followed by cyclization of the resulting chalcones using thiosemicarbazide. The anticipated chemical frameworks were confirmed by structural elucidation utilizing IR, 1H NMR, 13C NMR and HRMS studies. All the derivatives showed substantial binding affinities in molecular docking analysis using AutoDock Vina against EGFR kinase (PDB ID: 3POZ). Compound Py3 exhibited the highest docking score (-10.2 kcal/mol), surpassing the co-crystallized ligand O3P (-10.0 kcal/mol) and demonstrated interactions with key EGFR inhibitory residues, including Lys50, Thr95, Met98 and Val131. ADMET projections indicated low toxicity, excellent pharmacokinetic characteristics and synthetic accessibility. Furthermore, compound Py2 had the lowest IC50 value (44.47 µg/mL) in an in vitro cytotoxicity screening against MCF-7 breast cancer cells using the MTT test, indicating considerable activity. The structure-activity relationship analysis suggested that the presence of electron withdrawing substituents, especially chloro and nitro groups, enhances the cytotoxicity activity.

30 June 2025 in Current Cancer Therapy Reviews
Verified
Journal Article
Closed access
PDF file
DWDeepali Wanode
Deepali Wanode
DNDeweshri Nandurkar
Deweshri Nandurkar
RPRohini Palekar
Rohini Palekar
KBKumud Bhendarkar
Kumud Bhendarkar
PKPramod Khedekar
Pramod Khedekar
Angiogenesis reduction with VEGF/VEGFR (Vascular Endothelial Growth Factor/ Vascular Endothelial Growth Factor Receptor) inhibition is the target of our review. Angiogenesis is the development of blood vessels and affects cancer spread and progression. The angiogenesis process is triggered by a number of growth factors, including cytokines, VEGF, FGF (fibroblast growth factor), and PDGF (platelet-derived growth factor). VEGF and VEGFR are two factors that significantly impact the angiogenesis process. VEGFRs are Kinase Domain Receptors (KDRs). Upon activation, KDRs trigger autophosphorylation, which leads to tumor growth, metastasis, and cell proliferation. Numerous cancer types, including breast, renal, non-small cell lung, cervical, hepatocellular, and others, have been linked to overexpression of VEGFR. It has been established that VEGF/ VEGFR overexpression or gene amplification occurs in certain malignancies. Furthermore, an increasing amount of research has shown that blocking VEGF/VEGFR may enhance the effects of chemotherapy. In recent decades, several VEGF/VEGFR inhibitors have been developed that effectively inhibit the growth and progression of several malignancies in vivo and in vitro, suggesting that VEGF/VEGFR could be a novel target for therapeutic intervention. In this review, we started by quickly going over the composition, location, and physiological roles of VEGF/VEGFR during mitosis. The oncogenic function of VEGF/VEGFR in the development of cancer has then been covered. Lastly, we have discussed the prospective anticancer therapy provided by the clinically authorized VEGFR inhibitors.